Primary duodenal lymphoma: Successful rituximab treatment and evaluation by FDG-PET

Hepato-Gastroenterology

Volumn 54, Issue 78, 2007, Pages 1658-1661

  Tanaka, Fumio ^a   Tominaga, Kazunari ^a   Ochi, Masahiro ^a   Yamada, Takao ^a   Sasaki, Eiji ^a   Shiba, Masatsugu ^a   Watanabe, Toshio ^a   Fujiwara, Yasuhiro ^a   Uchida, Toshiyuki ^a   Oshitani, Nobuhide ^a   Higuchi, Kazuhide ^a   Arakawa, Tetsuo ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG; Duodenal neoplasms; Follicular lymphoma; Positron emission tomography; Rituximab

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GALLIUM CITRATE GA 67; RITUXIMAB;

AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DUODENAL FOLLICULAR LYMPHOMA; ECHOGRAPHY; ERADICATION THERAPY; FEMALE; FEVER; FOLLICULAR LYMPHOMA; FOLLOW UP; GASTROINTESTINAL TRACT SCINTISCANNING; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MESENTERY LYMPH NODE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR BIOPSY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DUODENAL NEOPLASMS; ENDOSCOPY; FEMALE; FLUORODEOXYGLUCOSE F18; GALLIUM RADIOISOTOPES; HELICOBACTER PYLORI; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; LYMPHOMA; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; RADIONUCLIDE IMAGING; TIME FACTORS;

EID: 35948962765     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457-2466.
2. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodkin's lymphoma. Blood 1997; 90:2188-2195.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
4. Tadahiko I, Tomoko O, Hirofumi F, Yasutsuna S, Yasuo M, Michinori O, Yoshitoyo K, Tomohiro K, Masaharu K, Yoshio K, Yukio K, Kensei T, and Members of the IDEC-C2B8 Study Group: Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001; 73:213-221.
5. Warburg O: On the origin of cancer cells. Science 1956; 123:309-314.
6. Gallagher BM, Fowler JS,Gutterson NI, MacGregor RR, Wan CN, Wolf AP: Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of (18F) 2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19:1154-1161.
7. Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M: Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5:397-400.
8. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC: A revised European-American classification of lymphoid neoplasms: a proposal from International Lymphoma Study Group. Blood 1994; 84:1361-1392.
9. Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, Franke WG, Ehninger G: Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115:793-800.
10. Yoshino T, Miyake K, Ichimura K, Tomohoko M, Nobuya O, Shuji H, Tadaatsu A: Increased incidence of follicular lymphoma in the duodenum. Am J Surg Pathol 2000; 24:688-693.
11. Nakamura T, Suzuki T, Matsuura A, Ohashi K, Yokoi T, Nakamura H: Clinocopathological features of MALT lymphoma and follicular lymphoma of the duodenum. Stomach and Intestine 2001; 36:1529-1540. (In Japanese with English abstract)
12. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328:1002-1006.
13. Vento S, Cainelli F, Longhi MS: Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue. Lancet Oncol 2002; 3:333-340.
14. Zuckerman E, Zuckerman T, Douer D, Qian D, Levine AM: Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer 1998; 83:1224-1230.
15. Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, Morrissey L, Greco FA: Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 2002; 20:4261-4267.
16. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel BA: Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004, 22:3248-3254.
17. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ: Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer. Results of a multicentre study. Eur J Nucl Med 1999; 26:1547-1552.
18. Kotzerke J, Guhlmann A, Moog F, Frickhofen N, Reske SN: Role of attenuation correction for fluorine-18fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma. Eur J Nucl Med 1999; 26:31-38.
19. 18F-FDG-PET) does not visualize follicular lymphoma of the duodenum. Ann Hematol 2004; 83:276-278.
20. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN: Lymphoma: role of wholebody 2-deoxy-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
21. Delbeke D, Martin WH, Morgan DS, Kinney MC, Feurer I, Kovalsky E, Arrowsmith T, Greer JP: 2-deoxy-2 (F18) fluoro-D-glucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma. Mol Imaging Biol 2002; 4:105-114.
22. Weber WA, Schwaiger M, Avril N: Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 2000; 27:683-687.